PharmaMar SALung cancerFDA approves atezolizumab–lurbinectedin for ES-SCLCThe U.S. FDA has approved atezolizumab and atezolizumab with hyaluronidase in combination with lurbinectedin as the first and only first-line maintenance therapy for adults with extensive-stage small … more ➔
U.S. Department of CommerceUS trade policyPharma Tariffs: US Government backtracksAfter the surprising announcement of a 100% tariff on all prescription drugs imported into the United States, the US government appears to be backtracking. Within a few days, its trade policy stance … more ➔
Rezon BioContract ManufacturingBiologics CDMO Rezon Bio leaves stealth modeRezon Bio has launched as a European contract development and manufacturing organisation (CDMO) for biologics. The new company has been created following the demerger of Polpharma Biologics into two … more ➔
Merus NVM&AGenmab swallows Merus in US$8bn dealDanish Genmab A/S has acquired the Dutch oncology specialist Merus NV for US$8bn in cash. The 41% premium over Merus’s share price at Friday is largely attributed to the bispecific EGFR x LGR5 antibody, … more ➔
Adobe stock photos - Alernon77 Licence dealMSD Secures Option on EVX-B3Danish Evaxion A/S hat optionally licenced its vaccine EVX-B3.developed with its AI-Immunology™ platform to Merck, Sharp & Dohme. MSD payed UIS$7.5m upfront and offers up to US$592m in milestone payments … more ➔
Adobe stock Photos - hkama US trade policyTrump Targets Overseas with 100%-TariffOvernight, US President Donald Trump broke previous tariff agreements with the United Kingdom and the EU, announcing that from 1 October, patented medicines not produced in the US will be subject to … more ➔
uniqure Gene therapyUniQure’s stocks up after AMT-130 trial winAmsterdam-based UniQure NV’s stocks made a 240% after-hours jump at Nasdaq after the company announced its Huntington gene therapy AMT-130 met the endpoints of a Phase II study and it will apply for … more ➔
VedaBio IncFinancing/PartneringSiemens Healthineers enters CRISPR diagnostics spaceSiemens Healthineers have participated in a US$25m Series A extension of the CRISPR diagnostics specialist VedaBio Inc and signed a strategic agreement. more ➔
Peter de Klerk from Must n Stum/PRNewsfoto/Revyvealternative proteinRevyve scaling up production by €24m financingWageningen-based food-tech scale-up Revyve has raised €24m in a Series B financing, bringing its total capital raised to more than €40 million. The company will use the proceeds to scale up its yeast-based … more ➔
Roche AGObesityRoche moves obesity asset CT-388 into Phase IIISwiss Roche AG will advance its injectable obesity lead CT-388 into Phase III studies starting in H1/2026. With combination therapies, the Swiss pharma major aims at becoming obesity company No. 3 by … more ➔
PharmaMar SA
U.S. Department of Commerce
Rezon Bio
Merus NV
Adobe stock photos - Alernon77 
Adobe stock Photos - hkama 
uniqure 
VedaBio Inc
Peter de Klerk from Must n Stum/PRNewsfoto/Revyve
Roche AG